In prostate cancer, MYC remodels the chromatin structure to stimulate cell growth and promote oncogenic signaling via hyperacetylation (17, 18) and it has been shown that these oncogenic effects are partly mediated by the epigenetic reader protein, bromodomain extra-terminal (BET) (58). This evidence concerns the gene MYC and prostate cancer.